Description
Product Characteristics: Glutamic Acid Decarboxylase (GAD) catalyzes the conversion of glutamate to gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain. There are two isoforms of GAD, GAD65 (GAD2) and GAD67 (GAD1) (65 and 67 kDa, respectively) encoded by two different genes. The two isoforms have distinct intraneuronal distribution in the brain. There is 64% amino acid identity between the two isoforms. The highest degree of diversity appears to be located at the N-terminus, which in GAD65 is required for targeting the enzyme to GABA-containing secretory vesicles. GAD65 is primarily found in nerve terminals. GAD67 has been thought to be primarily located in the nerve cell body and has been identified as a major autoantigen in type 1 diabetes.Rabbit Anti-GAD65+GAD67 Polyclonal Antibody is developed in rabbit using a KLH-coupled synthetic peptide within residues 550-600 of human GAD65 (Swiss Prot: Q05329) and GAD67 (Swiss Prot: Q99259).
Target Information: This gene encodes one of several forms of glutamic acid decarboxylase, identified as a major autoantigen in insulin-dependent diabetes. The enzyme encoded is responsible for catalyzing the production of gamma-aminobutyric acid from L-glutamic acid. A pathogenic role for this enzyme has been identified in the human pancreas since it has been identified as an autoantigen and an autoreactive T cell target in insulin-dependent diabetes. This gene may also play a role in the stiff man syndrome. Deficiency in this enzyme has been shown to lead to pyridoxine dependency with seizures. Alternative splicing of this gene results in two products, the predominant 67-kD form and a less-frequent 25-kD form. [provided by RefSeq, Jul 2008]